Allarity Therapeutics, Inc. (ALLR) has provided an announcement.
Allarity Therapeutics, Inc. has announced a significant breakthrough with its drug stenoparib, as it has shown clear clinical benefits in a Phase 2 trial for treating advanced recurrent ovarian cancer, leading to an early conclusion of the study. This development marks a notable milestone in the company’s endeavors to advance cancer treatment.
For detailed information about ALLR stock, go to TipRanks’ Stock Analysis page.
